BASF and Eight Partners Cooperate to Optimize Production Processes for Renewable-Based Products

A consortium of companies in the European process industry from the areas of biotechnology, renewable resources, chemistry, process engineering, equipment supply, as well as research organizations recently launched project PRODIAS (PROcessing Diluted Aqueous Systems). The project focuses on unlocking the potential of renewable-based products made via white biotechnology, by significantly decreasing production costs, increasing productivity and efficiency, lowering energy consumption, and accelerating process developments.
Under the consortial leadership of BASF, the partners include Cargill Haubourdin, France; University of Kaiserslautern, Germany; Imperial College London, UK; Alfa Laval, Sweden; GEA Messo PT, the Netherlands; Xendo, the Netherlands; UPM, Finland; and Enviplan, Germany. These partners will collaborate to develop cost and energy-efficient technologies for water purification, removal and product-recovery needed to support downstream processing in white biotechnology.
Using biotechnological methods such as fermentation or biocatalysis, in most cases the renewable-based products are produced as part of complex dilute aqueous mixtures from which they have to be purified. This includes the removal of a vast amount of water, making the downstream process energy intensive as it often requires many complex consecutive separation steps and thus hampers the cost-competitiveness of products from renewable resources. Furthermore, processing methods developed for chemical production are often used which are insufficiently adapted to biotechnological processes.
PRODIAS aims to address these challenges by developing and implementing cost-effective separation and purification technologies tailored for renewable resources in white biotechnology production processes. Its focus is to adapt separation techniques to the need of white biotechnology products and to design novel hybrid systems combining individual advantages, for example, selectivity and energy efficiency. The bioreactions (fermentations) and biocatalysis by which the valuable products are produced are subject to alteration and optimization, to enable more efficient and resource-saving downstream processing.
The total project budget is about €14 million with the European Union contributing €10 million. EU funding of the PRODIAS project is enabled via the Public-Private Partnership with SPIRE (Sustainable Process Industry through Resource and Energy Efficiency). SPIRE, in turn, is part of Horizon 2020, the EU framework program for research and innovation, which runs from 2014 to 2020 and comprises an €80 billion budget. In partnership with industry, the EU will invest in innovative technologies for sustainable processes.
Related News
-
News CPHI Online Trend Report – 2025 Pharma Packaging Prospects
The pharmaceutical packaging market has seen marked shifts in innovations, priorities, and focus over the last few years. With the rise of hit drugs like GLP-1 agonists and biologics requiring specialised packaging considerations, the strain of meeting... -
News Google-backed start-up raises US$600 million to support AI drug discovery and design
London-based Isomorphic Labs, an AI-driven drug design and development start-up backed by Google’s AI research lab DeepMind, has raised US$600 million in its first external funding round by Thrive Capital. The funding will provide further power t... -
News AstraZeneca to invest US$2.5 billion in Beijing R&D centre
Amid investigations of former AstraZeneca China head Leon Wang in 2024, AstraZeneca have outlined plans to establish its sixth global strategic R&D centre in China. Their aim is to further advance life sciences in China with major research and manufact... -
News US FDA adds haemodialysis bloodlines to devices shortage list
On March 14, 2025, the US FDA published an open letter to healthcare providers citing continuing supply disruptions of haemodialysis bloodlines, an essential component of dialysis machines. -
News Women in Pharma: Manufacturing personal and team success
Our monthly Women in Pharma series highlights the influential lives and works of impactful women working across the pharmaceutical industry, and how the industry can work towards making the healthcare industry and workplace more equitable and inclusive... -
News Pfizer may shift production back to US under Trump pharma tariffs
At the 45th TD Cowen annual healthcare conference in Boston, USA, Pfizer CEO Albert Bourla outlined the potential for Pfizer to shift its overseas drug manufacturing back to the US as pharmaceutical industry players weigh their options against Presiden... -
News Experimental drug for managing aortic valve stenosis shows promise
The new small molecule drug ataciguat is garnering attention for its potential to manage aortic valve stenosis, which may prevent the need for surgery and significantly improve patient experience. -
News Women in Pharma: Connecting accessible pharma packaging to patients – a Pharmapack Special
Throughout our Women in Pharma series, we aim to highlight how CPHI events encourage discussions around diversity, equity, and inclusion initiatives in the pharmaceutical industry.
Recently Visited
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance